Welcome to our dedicated page for Predictive Oncology SEC filings (Ticker: POAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Predictive Oncology鈥檚 SEC disclosures can feel like running a clinical trial of your own鈥攈undreds of pages on AI-driven drug screens, biobank valuations, and FDA-regulated devices. Whether you鈥檙e tracking STREAMWAY revenue or the PEDAL platform鈥檚 impact on R&D spend, the details hide deep inside 10-K footnotes and 8-K exhibits.
Stock Titan solves that problem. Our AI-powered summaries translate each Predictive Oncology annual report 10-K simplified, every quarterly earnings report 10-Q filing, and each Predictive Oncology 8-K material events explained into clear, actionable language. Need real-time alerts? We surface Predictive Oncology Form 4 insider transactions in real time, flagging executive stock sales before they hit the news. The platform covers the full spectrum鈥攑roxy statement executive compensation tables, registration statements, and even niche S-8 filings鈥攗pdated the minute EDGAR posts.
Looking for specific answers? Use our search prompts like 鈥渦nderstanding Predictive Oncology SEC documents with AI鈥� or 鈥淧redictive Oncology earnings report filing analysis鈥� and jump straight to AI-generated highlights: segment revenue trends, cash runway projections, and risk-factor changes. Monitor Predictive Oncology insider trading Form 4 transactions, compare R&D outlays quarter-over-quarter, or download clean tables for your own models. With comprehensive filing coverage, plain-English explanations, and machine-learning insights, Stock Titan turns complex biotech disclosures into practical intelligence investors actually use.
Predictive Oncology Inc. (NASDAQ: POAI) has entered into a $10 million Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. that gives the company the discretionary right, for up to 36 months, to issue common shares to the investor at 96% of the lowest daily VWAP over the three trading days following each advance notice. Prior to drawing on the facility, POAI must file and declare effective an SEC registration statement covering the resale of the shares issued.
Key structural limits
- Exchange Cap: 1,921,706 shares (19.99% of outstanding) unless shareholder approval is obtained or the average sale price is 鈮� $0.83.
- Beneficial-ownership cap: Investor cannot exceed 4.99% of outstanding voting power.
- Termination: Automatic at the earlier of 36 months or full draw; POAI may voluntarily terminate with five trading-days鈥� notice if no pending advances.
POAI has already paid a $25,000 structuring fee and issued 120,482 shares (1% of commitment) as a commitment fee. Net proceeds, which will vary with share price and draw frequency, are earmarked for working capital and general corporate purposes.
Investor implications
- Liquidity boost: The facility provides a readily accessible, moderately priced funding source without immediate debt obligations.
- Dilution risk: Potential issuance of up to ~20% of current shares鈥攁nd more with shareholder approval鈥攃ould pressure the share price if fully utilized.
- Pricing flexibility: Management can set a minimum acceptable price per advance, partially mitigating downside pricing risk.
FAQ
What is the current stock price of Predictive Oncology (POAI)?
What is the market cap of Predictive Oncology (POAI)?
What is the core focus of Predictive Oncology Inc?
How does the company generate revenue?
What are the primary technological innovations employed by the company?
How does Predictive Oncology contribute to personalized medicine?
What competitive advantages does Predictive Oncology hold in its industry?
How does the company ensure data integrity and clinical reliability?
Who are the primary customers and partners of Predictive Oncology?
How does the company address challenges in drug discovery?
